Last reviewed · How we verify

NCT06254885

Insertion Protocol of Convergent Transmucosal Design Implants

Status unknown NA Last updated 16 February 2024
What this trial tests

NA trial testing Equi-crestal Implant placement in Implant Site Reaction in 25 participants. Status unknown.

Timeline
14 February 2024
Primary endpoint
30 June 2024
30 June 2025

Quick facts

Lead sponsorUniversity of Cagliari
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment25
Start date14 February 2024
Primary completion30 June 2024
Estimated completion30 June 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Cagliari

Who can join

18 and older, any sex, with Implant Site Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this randomized clinical study is the evaluation of the peri-implant mucosal tissues and the marginal bone level, after positioning the transition shoulder from the intraosseous to the transmucosal portion, with an equicrestal position (at the level of the bone crest) or subcrestal (under the bone crest level).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Implant Site Reaction

Currently open trials in the same condition.

Other University of Cagliari trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06254885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing